Which funds are similar to Nippon India Pharma Fund Direct-Growth?
Funds similar to Nippon India Pharma Fund Direct-Growth in the Equity: Sectoral-Pharma category include ICICI Prudential Healthcare Fund Direct-Growth, SBI Healthcare Opportunities Fund Direct Plan-Growth, and DSP Healthcare Fund Direct-Growth. These funds follow a comparable investment mandate and are benchmarked against similar indices. You can compare them in detail — across returns, risk metrics, expense ratio, and portfolio composition — using the fund comparison tool on sharpely.
What is the rank of Nippon India Pharma Fund Direct-Growth in its category?
On a 3-year return basis Nippon India Pharma Fund Direct-Growth is ranked 11 out of 11 funds in the Equity: Sectoral-Pharma category as of 6 Sep 2026. On a 5-year return basis it ranks 7 out of 8. Consistently ranking in the top across multiple time periods is a stronger signal of fund quality than a single-period rank.
How does Nippon India Pharma Fund Direct-Growth's expense ratio compare to similar funds?
Nippon India Pharma Fund Direct-Growth has an expense ratio of 0.99%. The peers ICICI Prudential Healthcare Fund Direct-Growth has an expense ratio of 1.31% and SBI Healthcare Opportunities Fund Direct Plan-Growth has 1.04%. Over the long term, a higher expense ratio can meaningfully drag on returns, so it is worth evaluating whether the fund's performance justifies the additional cost.
How does Nippon India Pharma Fund Direct-Growth's AUM compare to similar funds?
Nippon India Pharma Fund Direct-Growth has an AUM of ₹9,279.11 crore. The peers ICICI Prudential Healthcare Fund Direct-Growth has an AUM of ₹6,802.61 crore and SBI Healthcare Opportunities Fund Direct Plan-Growth has ₹5,399.88 crore. A large AUM can sometimes limit a fund's ability to take meaningful positions in mid and small-cap stocks, as larger trades can move prices. This is particularly relevant for funds that invest outside large caps.
Which fund has the best 3-year returns in the Equity: Sectoral-Pharma?
The top performing fund in the Equity: Sectoral-Pharma category on a 3-year basis is UTI Healthcare Fund Direct-Growth with a CAGR of 24.47% as of 6 Sep 2026. Nippon India Pharma Fund Direct-Growth has delivered 18.93% CAGR over the same period, ranking 11 out of 11 funds. You can view and compare the full category ranking on sharpely.
How does Nippon India Pharma Fund Direct-Growth rank in risk-adjusted returns vs peers?
On a risk-adjusted basis, Nippon India Pharma Fund Direct-Growth has a Sharpe ratio of 0.92 compared to the Equity: Sectoral-Pharma average of 1.04 as of 6 Sep 2026. It ranks 10 out of 13 funds in its category on Sharpe ratio.
